Research programme: AIDS gene therapy - EUFETS
Latest Information Update: 20 Jul 2009
At a glance
- Originator EUFETS
- Class Gene therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 20 Jul 2009 Discontinued - Preclinical for HIV infections in Germany (unspecified route)
- 20 Jan 2005 Preclinical trials in HIV infections treatment in Germany (unspecified route)